Written by RTN Reporter
Thursday, 23 February 2012
A NEW combination of investigational drugs that successfully suppress the genotype 1 infection of Hepatitis C, the most difficult to treat, could become a reality within the next two years. In Spain, the virus affects around 800,000 people, causing cirrhosis and also cancer of the liver.
Dr. Jacob George, Professor of Gastroenterology and Hepatic Medicine at the University of Sydney in Australia, announced the findings at the Conference of the Asian Pacific Association for the Study of Liver Diseases, held in Taipei (Taiwan), promising results from a phase II study published in The New England Journal of Medicine.
Patients in whom treatment was not effective exclusively with PEG-interferon alfa and ribavirin were given a combination of two antiviral agents (daclatasvir and asunaprevir), eradicating the virus from the blood in "all patients who participated in the trial." The infection commonly occurs through needles; surgical practices; transfusions or transplants performed without correct hygiene measures. It may also be the result of unhygienic tattooing or piercing.
Who is doing the clinical trails on it?
ReplyDeletePlease advise
jenne griffin
It is Bristol-Myers Squibb. You can look up trials on clinicaltrails.gov.
ReplyDelete